Intestinal and arterial plasma thromboxane and prostacyclin levels in shock: effects of indomethacin.
The role of thromboxane and prostacyclin in circulatory shock of intestinal origin was investigated in anesthetized dogs by measuring their stable metabolites, thromboxane B2 (TXB2) and 6-keto-PGF1 alpha, respectively, in superior mesenteric vein (SMV), right ventricle (RV), and aorta during superior mesenteric artery occlusion-induced (SMAO) shock and by inhibiting prostanoid synthesis with indomethacin (IM). Release of the SMAO caused a dramatic decrease in mean arterial blood pressure and a significant increase in 6-keto-PGF1 alpha levels in SMV, RV, and aorta within 5 min. Thereafter, 6-keto-PGF1 alpha concentration decreased so that at 60-min postrelease it was not significantly different from the control values. TXB2 levels rose continuously during shock. IM significantly attenuated the magnitude of postocclusion hypotension and reduced both TXB2 and 6-keto-PGF1 alpha production.
Mózes
T
T
Department of Surgery III, Semmelweis University Medical School, Budapest, Hungary.
Wieszt
E
E
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D011464:Epoprostenol / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D008638:Mesenteric Arteries; D008641:Mesenteric Vascular Occlusion / Q000503:physiopathology*; D012769:Shock / Q000503:physiopathology*; D013928:Thromboxane A2 / Q000378:metabolism; D013929:Thromboxane B2 / Q000097:blood / Q000378:metabolism*
D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D007213:Indomethacin